Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Learn about retirement plans that might be better than a 401k. Enhance your retirement strategy with informed choices.
27,827 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
July can be a pivotal moment for travel stocks. Here are three clear reasons why Carnival stock may deserve a place o...
Apple sits near a record price, but its future may still be bright. This guide breaks down the numbers, the moat, and...
Rigetti Computing has dropped about 70% from its 52-week high. This article breaks down whether the dip offers real u...
Warren Buffett's move into a big oil stock has investors buzzing. We break down what this means for long-term fans of...
Starting with $1,000 doesn’t require luck or timing. This guide identifies the smartest Vanguard option for a straigh...
A major wealth manager just unveiled a multi-million-dollar stake in a commodity-focused ETF boosting income appeal. ...
SpaceX IPO plans could redefine the space economy, but Blue Origin is positioned to challenge. Learn how to evaluate ...
When a top investor steps up after a steep drop, it signals conviction. This deep dive looks at why First Beijing bou...
When a prominent fund makes a sizable stake reduction, it often signals more than profit-taking. This article breaks ...
A surge in Redwire shares mirrors a broader buzz around space stocks. Learn what’s driving the rally, what it means f...
A glamorous opal suite with a surprising backstory sheds light on how provenance, rarity, and celebrity connections c...